Table 1 Demographic characteristics of all patients and stratified between treatments
Characteristic | All cohort (n = 3775) | Macrolide-based (n = 1154) | Non-macrolide-based (n = 2621) | p-value |
|---|---|---|---|---|
Demographic | ||||
Male, n (%) | 2185 (57.9) | 642 (55.6) | 1543 (58.9) | 0.07 |
Age, mean (SD) | 67.6 (16.1) | 68.0 (16.2) | 67.4 (16.0) | 0.19 |
Charlson comorbidity index, mean (SD) | 6.5 (3.0) | 6.6 (3.0) | 6.5 (3.0) | 0.43 |
Laboratory variables at admission, mean (SD) | ||||
Haematocrit min, % | 30.6 (6.6) | 31.6 (6.7) | 30.2 (6.6) | < 0.001 |
Haemoglobin max, mg/dL | 11.3 (2.2) | 11.4 (2.3) | 11.2 (2.2) | 0.06 |
Platelets min, cell/mm3 | 205.3 (119.6) | 200.5 (104.0) | 207.4 (125.9) | 0.74 |
WBC min, cell/mm3 | 11.3 (10.0) | 11.5 (10.8) | 11.3 (9.6) | 0.73 |
WBC max, cell/mm3 | 15.1 (12.6) | 15.0 (14.7) | 15.1 (11.5) | 0.04 |
Anion gap max, mEq/L | 17.2 (4.9) | 17.3 (4.6) | 17.2 (5.0) | 0.11 |
Bicarbonate min, mEq/L | 22.3 (5.6) | 22.5 (5.7) | 22.3 (5.6) | 0.49 |
BUN max, mg/dL | 33.1 (25.3) | 32.3 (23.3) | 33.4 (26.1) | 0.99 |
Calcium max, mEq/L | 8.6 (0.9) | 8.6 (0.7) | 8.6 (0.9) | 0.05 |
Chloride min, mEq/L | 100.1 (6.9) | 99.0 (6.9) | 100.6 (6.9) | < 0.001 |
Creatinine min, mEq/L | 1.4 (1.4) | 1.4 (1.4) | 1.4 (1.4) | 0.82 |
Glucose min, mg/dL | 121.2 (44.8) | 123.3 (46.1) | 120.3 (44.1) | 0.04 |
Sodium max, mEq/L | 139.7 (5.5) | 139.5 (5.4) | 139.9 (5.6) | 0.30 |
Potassium max, mEq/L | 4.7 (0.9) | 4.8 (1.0) | 4.7 (0.9) | 0.001 |
Lymphocytes max, cell/mm3 | 1.5 (5.0) | 1.5 (6.5) | 1.4 (4.1) | 0.64 |
Neutrophils max, cell/mm3 | 11.4 (6.9) | 11.2 (7.0) | 11.5 (6.9) | 0.31 |
INR max | 1.8 (1.3) | 1.8 (1.3) | 1.7 (1.3) | 0.34 |
PT max, sec | 19.0 (13.6) | 19.1 (13.5) | 19.0 (13.6) | 0.06 |
PTT max, sec | 43.9 (28.4) | 42.6 (26.4) | 44.4 (29.2) | 0.67 |
Urine output, mL | 1752.4 (1246.4) | 1801.4 (1238.4) | 1730.8 (1249.6) | 0.05 |
Interventions, n (%) | ||||
HFNC | 118 (3.1) | 73 (6.3) | 45 (1.7) | < 0.001 |
Invasive ventilation | 1481 (39.2) | 370 (32.1) | 1111 (42.4) | < 0.001 |
Non-invasive ventilation | 151 (4.0) | 75 (6.5) | 76 (2.9) | < 0.001 |
Severity, n (%) | ||||
SAPS II | 38.5 (13.2) | 37.2 (12.1) | 39.1 (13.5) | < 0.001 |
Respiratory failure | 2213 (58.6) | 751 (65.1) | 1462 (55.8) | < 0.001 |
Septic shock | 1017 (26.9) | 311 (26.9) | 706 (26.9) | 0.98 |
ARDS | 42 (1.1) | 19 (1.6) | 23 (0.9) | 0.06 |
Other antibiotic treatments, n (%) | ||||
Quinolones | 1417 (37.5) | 246 (21.3) | 1171 (44.7) | < 0.001 |
Aetiology, n (%) | ||||
No aetiology | 970 (25.7) | 269 (23.3) | 701 (26.7) | 0.03 |
Atypical bacteria | 276 (7.3) | 46 (4.0) | 230 (8.8) | < 0.001 |
Typical bacteria | 198 (5.2) | 35 (3.0) | 163 (6.2) | < 0.001 |
P. aeruginosa or MRSA | 533 (14.1) | 95 (8.2) | 438 (16.7) | < 0.001 |
Fungi | 41 (1.1) | 19 (1.6) | 22 (0.8) | 0.04 |
Virus | 1 (0.0) | 0 (0) | 1 (0.0) | 0.67 |
Outcomes, n (%) | ||||
Hospital mortality | 610 (16.2) | 156 (13.5) | 454 (17.3) | 0.004 |
6 m mortality | 1398 (37.0) | 363 (31.5) | 1035 (39.5) | < 0.001 |
12 m mortality | 1648 (43.7) | 450 (39.0) | 1198 (45.7) | < 0.001 |